Literature DB >> 25054302

The potential of PARP inhibitors in neuro-oncology.

Ross Carruthers1, Anthony J Chalmers.   

Abstract

DNA damaging agents have an integral role in the treatment of brain tumors. Recent advances in our understanding of how cancer cells repair DNA damage have made it possible to consider modification of the DNA damage response as a way in which resistance to radiotherapy and chemotherapy might be overcome. PARP inhibitors are potent but nontoxic drugs that inhibit repair of DNA single-strand breaks and increase the cytotoxic effects of radiotherapy and alkylating chemotherapy agents, including temozolomide. PARP inhibitors have potential applications in neuro-oncology because there is increasing evidence that their radio- and chemo-sensitizing effects are tumor specific. This review explores the mechanisms of action of PARP inhibitors and describes their putative mechanisms of radio- and chemo-sensitization in the context of CNS oncology. The authors go on to review their development in recent clinical trials, with a focus on glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 25054302      PMCID: PMC6176825          DOI: 10.2217/cns.12.13

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  70 in total

Review 1.  Protein-protein interactions during mammalian DNA single-strand break repair.

Authors:  K W Caldecott
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

Review 2.  Homologous recombination in DNA repair and DNA damage tolerance.

Authors:  Xuan Li; Wolf-Dietrich Heyer
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

3.  PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.

Authors:  J C Amé; V Rolli; V Schreiber; C Niedergang; F Apiou; P Decker; S Muller; T Höger; J Ménissier-de Murcia; G de Murcia
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

4.  4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer.

Authors:  A Schlicker; P Peschke; A Bürkle; E W Hahn; J H Kim
Journal:  Int J Radiat Biol       Date:  1999-01       Impact factor: 2.694

5.  Influence of 5-aminoisoquinolin-1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischemia and after reperfusion.

Authors:  S Hendryk; Z P Czuba; H Jedrzejowska-Szypulka; E Szliszka; V A Phillips; M D Threadgill; W Krol
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

6.  Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Authors:  R A Daniel; A L Rozanska; E A Mulligan; Y Drew; H D Thomas; D J Castelbuono; Z Hostomsky; E R Plummer; D A Tweddle; A V Boddy; S C Clifford; N J Curtin
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

7.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

8.  5-Aminoisoquinolinone reduces renal injury and dysfunction caused by experimental ischemia/reperfusion.

Authors:  Prabal K Chatterjee; Bristi E Chatterjee; Helene Pedersen; Ahila Sivarajah; Michelle C McDonald; Helder Mota-Filipe; Paul A J Brown; Keith N Stewart; Salvatore Cuzzocrea; Michael D Threadgill; Christoph Thiemermann
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

Review 9.  Co-ordination of DNA single strand break repair.

Authors:  Grigory L Dianov; Jason L Parsons
Journal:  DNA Repair (Amst)       Date:  2006-11-22

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

View more
  6 in total

Review 1.  Enhancing Career Paths for Tomorrow's Radiation Oncologists.

Authors:  Neha Vapiwala; Charles R Thomas; Surbhi Grover; Mei Ling Yap; Timur Mitin; Lawrence N Shulman; Mary K Gospodarowicz; John Longo; Daniel G Petereit; Ronald D Ennis; James A Hayman; Danielle Rodin; Jeffrey C Buchsbaum; Bhadrasain Vikram; May Abdel-Wahab; Alan H Epstein; Paul Okunieff; Joel Goldwein; Patrick Kupelian; Joanne B Weidhaas; Margaret A Tucker; John D Boice; Clifton David Fuller; Reid F Thompson; Andrew D Trister; Silvia C Formenti; Mary-Helen Barcellos-Hoff; Joshua Jones; Kavita V Dharmarajan; Anthony L Zietman; C Norman Coleman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-05-22       Impact factor: 7.038

Review 2.  Medulloblastoma and the DNA Damage Response.

Authors:  Leon F McSwain; Kiran K Parwani; Shubin W Shahab; Dolores Hambardzumyan; Tobey J MacDonald; Jennifer M Spangle; Anna Marie Kenney
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 3.  Therapeutic Options for Brain Metastases in Gynecologic Cancers.

Authors:  Adeola Akapo; Kseniya Anishchenko; Carolyn Lefkowits; Ashley L Greenwood
Journal:  Curr Treat Options Oncol       Date:  2022-10-18

4.  PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.

Authors:  Ben Fulton; Susan C Short; Allan James; Stefan Nowicki; Catherine McBain; Sarah Jefferies; Caroline Kelly; Jon Stobo; Anna Morris; Aoife Williamson; Anthony J Chalmers
Journal:  Clin Transl Radiat Oncol       Date:  2017-11-21

Review 5.  Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.

Authors:  Liesbeth Everix; Shankari Nair; Cathryn H S Driver; Ingeborg Goethals; Mike M Sathekge; Thomas Ebenhan; Charlot Vandevoorde; Julie Bolcaen
Journal:  Cancers (Basel)       Date:  2022-04-03       Impact factor: 6.639

Review 6.  Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.

Authors:  Marianna Mekhaeil; Kumlesh Kumar Dev; Melissa Jane Conroy
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.